Fast cardiac bone scan for transthyretin cardiac amyloidosis
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests a faster heart-imaging method (bone scan) for people suspected of having transthyretin cardiac amyloidosis, a heart condition caused by abnormal protein deposits. The goal is to see if the faster scan gives the same clear images as the standard scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a bone scan (a test that uses a small amount of radiation to check for protein deposits in the heart) between April 2024 and April 2025.
- Your doctor ordered this scan because they thought you might have transthyretin cardiac amyloidosis (a specific type of amyloidosis affecting the heart).
- You do not object to your medical data being used for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a type of heart condition called transthyretin cardiac amyloidosis changes over time, using a special imaging test called a bone scan. The goal is to see if the scan can help track the disease and potentially improve care.
This study looks at past bone scans to find signs of a heart condition called amyloidosis, where abnormal proteins build up in the heart. It may help identify more people with this condition and improve future diagnosis.
This study tests a new PET imaging agent (evuzamitide) to see if it can better detect cardiac amyloidosis when earlier tests were unclear. It may help confirm if the heart problem is related to TTR amyloid and guide further care.
This trial is looking at leftover tissue from past spine surgeries to see if it contains signs of a heart condition called TTR amyloidosis. It may help find people who have this condition early.
This study uses a special PET scan tracer to see how consistent the images are in people with heart amyloidosis (a buildup of abnormal protein in the heart) and in people without the condition. The goal is to improve diagnosis and monitoring.
This study tests a new PET imaging tracer called [18F]FT8 to see if it can better detect amyloid protein buildup in the heart. It may help doctors diagnose and monitor cardiac amyloidosis more accurately.
Hear when a new Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.